Gene · 22806
Papers2,106
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,106
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Insulitis in human type 1 diabetes: lessons from an enigmatic lesion. | Eur J Endocrinol | 2024 | 38231086 | PubTator, text mining | PubMed |
| Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. | Nat Commun | 2024 | 38228616 | PubTator, text mining | PubMed |
| Genetic variations in IKZF3, LET7-a2, and CDKN2B-AS1: Exploring associations with metabolic syndrome susceptibility and clinical manifestations. | J Clin Lab Anal | 2024 | 38193570 | PubTator, text mining | PubMed |
| IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development. | Nat Immunol | 2024 | 38182668 | PubTator, text mining | PubMed |
| Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores. | J Med Chem | 2024 | 38170610 | PubTator, text mining | PubMed |
| Induced protein degradation for therapeutics: past, present, and future. | J Clin Invest | 2024 | 38165043 | PubTator, text mining | PubMed |
| Evolution of the Ikaros family transcription factors: From a deuterostome ancestor to humans. | Biochem Biophys Res Commun | 2024 | 38134477 | PubTator, text mining | PubMed |
| MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. | Blood Adv | 2024 | 38113470 | PubTator, text mining | PubMed |
| Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. | Bioact Mater | 2024 | 38059121 | PubTator, text mining | PubMed |
| Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis. | Brain | 2024 | 38038362 | PubTator, text mining | PubMed |
| IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children. | Cancer | 2024 | 38018448 | PubTator, text mining | PubMed |
| Disease-associated AIOLOS variants lead to immune deficiency/dysregulation by haploinsufficiency and redefine AIOLOS functional domains. | J Clin Invest | 2024 | 38015619 | PubTator, text mining | PubMed |
| A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis. | Blood Adv | 2024 | 37939259 | PubTator, text mining | PubMed |
| ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma. | Blood Cancer Discov | 2024 | 37934799 | PubTator, text mining | PubMed |
| Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. | Blood Cancer Discov | 2024 | 37767768 | PubTator, text mining | PubMed |
| Recent advances in targeted protein degraders as potential therapeutic agents. | Mol Divers | 2024 | 36790583 | PubTator, text mining | PubMed |
| Transcriptional profiling specifies the pathogen-specific human host response to infectious keratitis. | Front Cell Infect Microbiol | 2023 | 38274739 | PubTator, text mining | PubMed |
| The genetic risk of acute lymphoblastic leukemia and its implications for children of Latin American origin. | Front Oncol | 2023 | 38264740 | PubTator, text mining | PubMed |
| Atopic March or Atopic Multimorbidity-Overview of Current Research. | Medicina (Kaunas) | 2023 | 38256282 | PubTator, text mining | PubMed |
| An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma. | Contemp Oncol (Pozn) | 2023 | 38239862 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22806/papers?page=8